Skip to main content

Nu Eyne develops eye wearable to heal dry eye syndrome

Tinuku - South Korean medtech startup Nu Eyne develops eye wearable aimed to heal DES via weak electric stimulation. Laser eye surgery, performed as LASIK or LASEK, has become a common medical procedure over the past decade. But for many patients, improved eyesight comes at the cost of a new, debilitating side effect dry eye syndrome.

Dry eye syndrome or DES is a condition in which your eyes are unable to produce enough tears to provide sufficient lubrication and moisture on the surface of the eyes, causing constant irritation and inflammation. In the case of laser eye surgery, DES is typically caused by damages to the corneal nerves.

Tinuku Nu Eyne develops eye wearable to heal dry eye syndrome

On top of its links to laser eye surgery, DES has been becoming more prevalent in the past few years, with increased smartphone usage as well as heightened air pollution. Despite the circumstances, DES has yet to find a treatment that can reverse or heal the disease. There are only medications, eye drops or lubricants, for symptom relief.

Targeting this treatment gap, South Korean medical technology startup Nu Eyne has set out to develop and commercialize a first-in-class medical device that could heal DES by instigating optic nerve regeneration.

The cornea, the eye’s outermost layer, is one of the most sensitive organs of the human body, with a highly dense nerve network. Yet much of these nerves are carved off during laser eye surgery, with little that can be done to reverse the “damage.”

Nu Eyne is developing a device, shaped like a pair of 3D glasses, which delivers weak electric currents to a person’s corneal nerves via a patch that touches the skin around the eyes. The electrical stimulation mimics the body’s endogenous wound healing mechanism, and in turn induces nerve regeneration.

“Until now, there hadn’t been a viable method of treating corneal nerve damage, the main cause of dry eye syndrome and swelling (within the cornea) after laser eye surgery,” Nu Eyne founder and CEO Kim Do-hyoung said.

Upon completing the development of the device, the firm has been conducting animal tests in partnership with the Samsung Medical Center’s Department of Ophthalmology. It is currently preparing to initiate clinical trials for the device in December, with aims to obtain medical device approval by December 2019.

“We are developing our product with aims to become the maker of the world’s first ‘bioelectronic medicine’ for DES,” Kim said.

Bioelectronic medicine refers to a rising category of medicine in which illnesses are treated by administering direct electric stimulation to an organ, rather than through the use of drugs or chemical treatments. Nu Eyne’s device falls in this category, Kim said.

The startup was co-founded in 2017 by Kim, who holds a Ph.D. in biomedical engineering from Hanyang University and has worked for the US-based Mayo Clinic and local health-tech startup Ybrain, and three fellow engineer-entrepreneurs with experience in medical device development, patenting and approval. Nu Eyne develops eye wearable to heal dry eye syndrome

Though the eventual goal is to treat all cases of DES, Nu Eyne is initially developing its product with post-LASEK and LASIK patients, who experience DES due to corneal damage, as the primary patient target.

During laser eye surgery, corneal nerve bundles are removed as a whole, impairing the eye’s sensitivity and tear-producing mechanisms. Even with time, most of these nerves do not grow back, and patients will go on to live with the consequences, one of which is DES.

“People get LASIK or LASEK for improved eyesight. But if another element of the eye is damaged in the process, is it really productive? This is why we saw a need to develop our device,” Kim said.

The size of the potential market is big. In Korea alone, around 2.1 million people are diagnosed with DES annually, according to Korea’s Health Insurance and Review Assessment Service. And an estimated 200,000 people receive laser eye surgeries every year, according to Nu Eyne.

“In Europe, there are similar CE-certified devices that use electrical optic nerve stimulation to treat conditions like glaucoma. We believe that this precedent, combined with strong clinical evidence, will enable us to swiftly earn regulatory approval,” Kim said.

After rolling out its product in the Korean market, the startup said it also hopes to bring the technology to Europe as well as Southeast Asia, where vision correction surgeries are becoming more popular.

Located at the city-run Seoul Bio Hub, Nu Eyne is currently backed by local startup accelerator Futureplay and the government-run TIPS program. It is also the winner of last year’s Seoul Innovation Quickfire Challenge hosted by Johnson & Johnson.


Popular posts

Conservative cleric vice president candidate of Indonesia, abstentions rose

Tinuku - Indonesian President Joko Widodo chose an elderly Muslim cleric Ma'ruf Amin as vice presidential candidate for the 2019 presidential election to become a red record for human rights activists. The figure who actively strives to criminalize minorities and sexuality is seen as a way to reverse human rights enforcement.

Lokataru's director, Haris Azhar, is still campaigning not to elect the presidential and vice presidential candidates. The declaration of two candidate pairs, especially the choice by Joko Widodo to Ma'ruf Amin as vice president and presidential candidate Prabowo Subianto on Sandiaga Uno as vice president, strengthened the minds of human rights activists.

"It's still the same. In fact, it is increasingly proven. From a human rights perspective, all candidates are violators of human rights. So I think the four candidates are the same, not friendly to human rights, not friendly to the environment," said Azhar told to Deutsche Welle Indones…

Ant Financial entered Indonesia in partnership with Emtek

Tinuku - Alibaba Group’s Ant Financial Services is making its first foray into Indonesia with plans to launch a new mobile platform for payment and other financial services in partnership with a local firm.

Ant Financial, operator of China’s popular online payment platform Alipay, announced on Wednesday that it will set up a joint venture with Indonesian digital company Emtek.

Without disclosing the size of the investment, the two companies said the joint venture will leverage Ant Financial’s experience and know-how in mobile payment, digital financial innovations, risk control and cloud computing.

To begin with, the new payment platform will be offered on BBM, Indonesia’s most commonly used messenger application, which is operated by a subsidiary of Emtek and has a user base of over 63 million monthly active users.

“Ant Financial has proven know-how in delivering payment and other financial solutions to a large and growing mobile audience in China and enabling its partners globally, …

Samsung Bioepis and Takeda plans clinical trials new drug

Tinuku - Samsung Bioepis said Monday that it plans to soon start phase 1 clinical trials for its first new drug candidate in development with Japan’s Takeda Pharmaceutical, setting a fresh milestone in the South Korean drugmaker’s push into new drug development.

The therapeutic candidate, SB26, also known as TAK-671, is an ulinastatin-Fc fusion protein to treat severe acute pancreatitis. It is the first result of the new drug development collaboration partnership signed by the two companies in August 2017. Samsung Bioepis spokesperson confirmed the upcoming clinical trials will be held in the US only, though the exact start date for the trials remain undisclosed.

Samsung Bioepis said, the study, randomized, double-blind, placebo-controlled and involving single and multiple dose escalation, will assess the safety, tolerability and pharmacokinetics of intravenous injections of SB26 in healthy volunteers. The results of the study are expected in the third quarter of 2020.

“The upcoming c…

Indonesia eyes plan to help startups expand across southeast Asia

Tinuku - Indonesia wants southeast Asian nations to cooperate in helping startups in the region worth at least $1 billion expand outside their home countries, the communication minister said on Friday. The effort aims to keep foreign startups from dominating a market of 640 million people by assisting the region’s estimated seven to ten unicorns, or companies that have attained a valuation of $1 billion without tapping the stock markets.

“I’ve discussed this strategy with other ministers in Southeast Asia and have offered to everyone to adopt existing unicorns and have a presence in each other’s countries,” Minister of Communication Rudiantara said in an interview.

“I’m really passionate about the issue and have discussed it at our last Association of Southeast Asian Nations ministers’ meeting,” he said at his office, adding that he would discuss the matter again at the next meeting of ASEAN ministers in Bali.

The suggestion drew a positive response from ministers from Thailand and Si…